FTC Orders Illumina to Divest Cancer Detection Test Maker Grail FTC Orders Illumina to Divest Cancer Detection Test Maker Grail

The US Federal Trade Commission on Monday ordered Illumina to divest cancer diagnostic test maker Grail, finding that its ownership would stifle competition in the US market for cancer tests.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news